Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in H1 2022 revenue, up 27.3% year-on-year (YOY), driven by commercialization of six novel drugs. R&D spending hit RMB 652 million (USD 94.4 million), while net profits fell 88.8% YOY to RMB 62 million (USD 8.9 million).
Commercial Highlights
- Six New Drugs: Generated RMB 1.76 billion (USD 254.9 million) in sales, up 44.8% YOY, led by CNS products edaravone and borneol (65.4% of total revenue).
- Trilaciclib: A first-in-class CDK4/6 inhibitor licensed from G1 Therapeutics, conditionally approved in July 2023 for extensive-stage small cell lung cancer (ES-SCLC), with commercial launch expected in Q4 2023.
R&D Pipeline
Simcere’s 60+ novel drug pipeline includes 16 candidates in 20 clinical trials. Recent milestones:
- 5 IND Approvals: Secured during H1 2022.
- 9 FPI/FIH Trials: Initiated, enrolling over 1,000 subjects.
- Strategic Shift: Reallocated funds from cell therapies (CD19 CAR-T, BCMA CAR-T) to oncology products like trilaciclib, SIM0395, and docetaxel polymer micelles.-Fineline Info & Tech
